



Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference

1/12/2023

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the B. Riley Securities 3rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET.

A live webcast of the presentation will be available through the Investor Relations section of Geron's website under **Events**. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20230112005297/en/>

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation